Patients with MG and anti‐NRIP autoantibody showed a trend to have unstable MG course (requiring titration of MG‐specific medication within 1 year) compared with those without anti‐NRIP autoantibodies, although the difference did not reach statistical significance (P = 0.077). The gene discussed is DCAF6; the disease is myasthenia gravis.